Tower Research Capital (TRC)’s Curanex Pharmaceuticals CURX Stock Holding History
Bought
Maintained
Sold
Other funds holding CURX
Tower Research Capital (TRC)'s CURX Position: Q3 2026 in Review
Tower Research Capital (TRC) increased its Curanex Pharmaceuticals (CURX) stake by 1,446% in Q3 2026, buying an estimated $3.19K and bringing the position to 773 shares worth $3.89K. The position accounts for ﹤0.01% of the portfolio, ranked #4830.
Tower Research Capital (TRC) first reported a position in CURX in Q2 2026 and has held it in 2 quarters since. 2 funds tracked by Wall St. Rank hold CURX as of Q3 2026.
- Tower Research Capital (TRC) held 773 shares of Curanex Pharmaceuticals worth $3.89K as of Q3 2026.
- Tower Research Capital (TRC) bought 723 Curanex Pharmaceuticals shares in Q3 2026, an estimated $3.19K.
- Curanex Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #4830 holding.
- Tower Research Capital (TRC) first reported a position in Curanex Pharmaceuticals in Q2 2026 and has held it in 2 quarters since.
- 2 funds tracked by Wall St. Rank held Curanex Pharmaceuticals as of Q3 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.